Detalhe da pesquisa
1.
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
Cancer
; 130(1): 41-50, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37658645
2.
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
Hematol Oncol
; 42(1): e3216, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37772620
3.
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Hematol Oncol
; 42(1): e3249, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38287529
4.
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey.
Ann Hematol
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630129
5.
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
Br J Haematol
; 203(3): 416-425, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37580908
6.
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.
Blood
; 135(15): 1244-1254, 2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32006000
7.
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Br J Haematol
; 193(2): 280-289, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476434
8.
Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia.
Haematologica
; 106(9): 2345-2353, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32732360
9.
SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
Haematologica
; 106(12): 3125-3135, 2021 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33121237
10.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Eur J Haematol
; 106(4): 493-499, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33378569
11.
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.
Haematologica
; 105(6): 1613-1620, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582547
12.
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.
Haematologica
; 105(2): 448-456, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31371416
13.
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.
Eur J Haematol
; 104(6): 581-587, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107795
14.
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.
Br J Haematol
; 185(3): 468-479, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30768678
15.
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).
Br J Haematol
; 185(4): 713-717, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30793297
16.
Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.
Int J Mol Sci
; 20(21)2019 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31683978
17.
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Haematologica
; 103(7): 1209-1217, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29674504
18.
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Ann Hematol
; 97(6): 1009-1018, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29442162
19.
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
Am J Hematol
; 98(7): E157-E160, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37067157
20.
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
Am J Hematol
; 98(2): E24-E27, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36349541